MUTYH and cancer: Approaches that exploit DNA repair deficiencies in cancer cells have had significant success in a variety of cancers, most notably PARP inhibitors in homologous recombination-deficient tumours .[35], [36], [37], [38] This study explored the potential to do the same in PDAC, but using an approach that targets the glycosylase MYH instead of an underlying mutation.